165 related articles for article (PubMed ID: 35715395)
21. Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans.
Sun W
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883528
[TBL] [Abstract][Full Text] [Related]
22. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
Xu G; Li Y; Zhang S; Peng H; Wang Y; Li D; Jin T; He Z; Tong Y; Qi C; Wu G; Dong K; Gou J; Liu Y; Xiao T; Qu J; Li L; Liu L; Zhao P; Zhang Z; Yuan J
Cell Res; 2021 Dec; 31(12):1230-1243. PubMed ID: 34663909
[TBL] [Abstract][Full Text] [Related]
24. Characterization and functional interrogation of the SARS-CoV-2 RNA interactome.
Labeau A; Fery-Simonian L; Lefevre-Utile A; Pourcelot M; Bonnet-Madin L; Soumelis V; Lotteau V; Vidalain PO; Amara A; Meertens L
Cell Rep; 2022 Apr; 39(4):110744. PubMed ID: 35477000
[TBL] [Abstract][Full Text] [Related]
25. Metabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target-Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
Puthanveetil P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830743
[TBL] [Abstract][Full Text] [Related]
26. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
27. Lipid Accumulation in Host Cells Promotes SARS-CoV-2 Replication.
Seitz T; Setz C; Rauch P; Schubert U; Hellerbrand C
Viruses; 2023 Apr; 15(4):. PubMed ID: 37113005
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
30. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.
Odak I; Schultze-Florey CR; Hammerschmidt SI; Ritter C; Willenzon S; Friedrichsen M; Ravens I; Sikora R; Bayir LM; Gutierrez Jauregui R; Bernhardt G; Stankov MV; Cossmann A; Hansen G; Krey T; Cornberg M; Koenecke C; Behrens GMN; Bošnjak B; Förster R
Front Immunol; 2022; 13():863039. PubMed ID: 35359969
[TBL] [Abstract][Full Text] [Related]
32. Quasi-species nature and differential gene expression of severe acute respiratory syndrome coronavirus 2 and phylogenetic analysis of a novel Iranian strain.
Ghorbani A; Samarfard S; Ramezani A; Izadpanah K; Afsharifar A; Eskandari MH; Karbanowicz TP; Peters JR
Infect Genet Evol; 2020 Nov; 85():104556. PubMed ID: 32937193
[TBL] [Abstract][Full Text] [Related]
33. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
[TBL] [Abstract][Full Text] [Related]
34. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of Cell Signaling by SARS-CoV-2.
Suryawanshi RK; Koganti R; Agelidis A; Patil CD; Shukla D
Trends Microbiol; 2021 Mar; 29(3):224-237. PubMed ID: 33451855
[TBL] [Abstract][Full Text] [Related]
36. RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity.
Yaniv K; Ozer E; Lewis Y; Kushmaro A
Water Res; 2021 Dec; 207():117808. PubMed ID: 34753092
[TBL] [Abstract][Full Text] [Related]
37. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
Bojkova D; Klann K; Koch B; Widera M; Krause D; Ciesek S; Cinatl J; Münch C
Nature; 2020 Jul; 583(7816):469-472. PubMed ID: 32408336
[TBL] [Abstract][Full Text] [Related]
38. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
39. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges.
Thakur N; Gallo G; Newman J; Peacock TP; Biasetti L; Hall CN; Wright E; Barclay W; Bailey D
J Gen Virol; 2022 Apr; 103(4):. PubMed ID: 35377298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
